Immunovant Net Debt from 2010 to 2026

IMVT Stock

USD 26.18 0.16 0.61%

Immunovant Net Debt yearly trend continues to be comparatively stable with very little volatility. Net Debt is likely to outpace its year average in 2026. Net Debt is the total debt of Immunovant minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2019-03-31

Previous Quarter

-598.9 M

Current Value

-521.9 M

Quarterly Volatility

201.6 M

Covid

Check Immunovant financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunovant's main balance sheet or income statement drivers, such as Depreciation And Amortization of 322.3 K, Interest Expense of 0.0 or Selling General Administrative of 93.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.0. Immunovant financial statements analysis is a perfect complement when working with Immunovant Valuation or Volatility modules.

Build AI portfolio with Immunovant Stock

Check out the analysis of Immunovant Correlation against competitors.

For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.

Latest Immunovant's Net Debt Growth Pattern

Below is the plot of the Net Debt of Immunovant over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Immunovant's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunovant's overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Immunovant Net Debt Regression Statistics

	Arithmetic Mean	(233,120,419)
	Coefficient Of Variation	(123.39)
	Mean Deviation	262,776,257
	Median	(25,000)
	Standard Deviation	287,646,902
	Sample Variance	82740.7T
	Range	713.8M
	R-Value	(0.89)
	Mean Square Error	18206.8T
	R-Squared	0.79
	Slope	(50,748,064)
	Total Sum of Squares	1323851.8T

Immunovant Net Debt History

	2026	-610.4 M
	2025	-642.5 M
	2024	-713.9 M
	2023	-635.2 M
	2022	-375.3 M
	2021	-491.5 M
	2020	-396.7 M

Other Fundumenentals of Immunovant

Net Debt To E B I T D A

Immunovant Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Accounts Payable	Total Liab	Total Current Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Net Receivables	Capital Surpluse	Deferred Long Term Liab	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment
Total Assets		1.0	0.86	0.89	0.99	1.0	-0.9	-0.98	-0.96	0.24	0.9	-0.86	0.95	-0.64	0.94	0.95	-0.11	0.94	0.89
Total Stockholder Equity	1.0		0.86	0.89	0.98	1.0	-0.9	-0.98	-0.96	0.24	0.9	-0.86	0.95	-0.64	0.94	0.95	-0.11	0.94	0.89
Net Tangible Assets	0.86	0.86		0.71	0.83	0.86	-0.98	-0.92	-0.76	0.35	0.97	-0.91	0.93	-0.26	0.95	0.93	0.13	0.95	0.96
Accounts Payable	0.89	0.89	0.71		0.91	0.89	-0.71	-0.84	-0.85	0.49	0.72	-0.67	0.81	-0.67	0.77	0.81	-0.19	0.77	0.75
Total Liab	0.99	0.98	0.83	0.91		0.99	-0.86	-0.95	-0.97	0.24	0.89	-0.84	0.92	-0.67	0.93	0.92	-0.09	0.93	0.88
Total Current Assets	1.0	1.0	0.86	0.89	0.99		-0.9	-0.98	-0.96	0.24	0.9	-0.86	0.95	-0.64	0.94	0.95	-0.11	0.94	0.89
Current Deferred Revenue	-0.9	-0.9	-0.98	-0.71	-0.86	-0.9		0.95	0.82	-0.27	-0.96	0.91	-0.92	0.34	-0.95	-0.92	-0.05	-0.95	-0.95
Net Debt	-0.98	-0.98	-0.92	-0.84	-0.95	-0.98	0.95		0.94	-0.28	-0.95	0.89	-0.97	0.48	-0.97	-0.98	0.07	-0.97	-0.94
Retained Earnings	-0.96	-0.96	-0.76	-0.85	-0.97	-0.96	0.82	0.94		-0.11	-0.87	0.77	-0.92	0.59	-0.91	-0.92	0.2	-0.91	-0.86
Net Receivables	0.24	0.24	0.35	0.49	0.24	0.24	-0.27	-0.28	-0.11		0.25	-0.24	0.23	-0.06	0.21	0.24	0.06	0.21	0.31
Capital Surpluse	0.9	0.9	0.97	0.72	0.89	0.9	-0.96	-0.95	-0.87	0.25		-0.9	0.97	-0.31	0.99	0.97	0.04	0.99	0.99
Deferred Long Term Liab	-0.86	-0.86	-0.91	-0.67	-0.84	-0.86	0.91	0.89	0.77	-0.24	-0.9		-0.86	0.38	-0.92	-0.86	-0.38	-0.92	-0.85
Net Invested Capital	0.95	0.95	0.93	0.81	0.92	0.95	-0.92	-0.97	-0.92	0.23	0.97	-0.86		-0.39	0.98	1.0	-0.07	0.98	0.96
Short Long Term Debt	-0.64	-0.64	-0.26	-0.67	-0.67	-0.64	0.34	0.48	0.59	-0.06	-0.31	0.38	-0.39		-0.39	-0.39	0.23	-0.39	-0.3
Capital Stock	0.94	0.94	0.95	0.77	0.93	0.94	-0.95	-0.97	-0.91	0.21	0.99	-0.92	0.98	-0.39		0.98	0.06	1.0	0.97
Net Working Capital	0.95	0.95	0.93	0.81	0.92	0.95	-0.92	-0.98	-0.92	0.24	0.97	-0.86	1.0	-0.39	0.98		-0.07	0.98	0.96
Short Term Debt	-0.11	-0.11	0.13	-0.19	-0.09	-0.11	-0.05	0.07	0.2	0.06	0.04	-0.38	-0.07	0.23	0.06	-0.07		0.06	-0.03
Common Stock	0.94	0.94	0.95	0.77	0.93	0.94	-0.95	-0.97	-0.91	0.21	0.99	-0.92	0.98	-0.39	1.0	0.98	0.06		0.97
Property Plant Equipment	0.89	0.89	0.96	0.75	0.88	0.89	-0.95	-0.94	-0.86	0.31	0.99	-0.85	0.96	-0.3	0.97	0.96	-0.03	0.97

Click cells to compare fundamentals

About Immunovant Financial Statements

Immunovant shareholders use historical fundamental indicators, such as Net Debt, to determine how well the company is positioned to perform in the future. Although Immunovant investors may analyze each financial statement separately, they are all interrelated. The changes in Immunovant's assets and liabilities, for example, are also reflected in the revenues and expenses on on Immunovant's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Net Debt	-642.5 M	-610.4 M
Net Debt To EBITDA	1.47	1.31

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Immunovant Stock Analysis

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Immunovant Net Debt from 2010 to 2026

Latest Immunovant's Net Debt Growth Pattern

Immunovant Net Debt Regression Statistics

Immunovant Net Debt History

Other Fundumenentals of Immunovant

Immunovant Net Debt component correlations

About Immunovant Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Immunovant Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY